What Your Broker of Record Isn't Showing You at Renewal

Every year, employers sit through renewal meetings that follow a remarkably similar script. The broker presents claims data, pharmacy trend reports, utilization summaries, market benchmarks, and projected renewal increases. What is less familiar is questioning whether the information being presented is actually sufficient to manage long-term healthcare costs.

Most renewal discussions are focused on explaining what happened during the previous year. They identify the largest claims, the most expensive medications, the fastest-growing diagnostic categories, and the factors that contributed to the upcoming renewal increase. While this information is important, it is also inherently retrospective. It explains the past far better than it predicts the future.

The Rise of GLP-1 Medications Exposes the Problem

The growing use of GLP-1 medications has made this limitation more visible. When renewal discussions focus exclusively on treatment costs, employers may miss the larger trend developing underneath the claims data. The medication is not the underlying problem. The medication is a response to the underlying problem. The real issue is the prevalence of metabolic disease within the population.

The Question Every Employer Should Ask

The next time an employer sits down for a renewal meeting, there is a simple question worth asking: "We know what our healthcare costs were last year. How do we know whether our population is becoming healthier?" It is a straightforward question. It is also one that many organizations struggle to answer.